TEVA LABORATORIES UK LIMITED
Get an alert when TEVA LABORATORIES UK LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-12-26 (in 7mo)
Last made up 2025-12-12
Watchouts
None on the register
Cash
—
Latest balance sheet
Net assets
£14M
-79.7% vs 2023
Employees
0
Average over period
Profit before tax
£54M
-35% vs 2023
Name history
Renamed 2 times since incorporation
- TEVA LABORATORIES UK LIMITED 2018-07-24 → present
- FOREST LABORATORIES UK LIMITED 2002-04-05 → 2018-07-24
- PHARMAX LIMITED 1954-05-03 → 2002-04-05
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £23,672,000 | £8,887,000 | |
| Operating profit | £77,978,000 | £49,840,000 | |
| Profit before tax | £83,806,000 | £54,465,000 | |
| Net profit | £65,516,000 | £39,288,000 | |
| Cash | — | — | |
| Total assets less current liabilities | £67,974,000 | £13,817,000 | |
| Net assets | £67,974,000 | £13,817,000 | |
| Equity | £67,974,000 | £13,817,000 | |
| Average employees | 0 | 0 | |
| Wages | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | 329.4% | 560.8% | |
| Net margin | 276.8% | 442.1% | |
| Return on capital employed | 114.7% | 360.7% | |
| Gearing (liabilities / total assets) | 32.4% | 73.8% | |
| Current ratio | 4.67x | 1.39x | |
| Interest cover | 5998.31x | — |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Azets Audit Services Limited
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The directors believe that preparing the financial statements on a going concern basis is appropriate due to the continued financial support of Teva Pharmaceuticals Europe B.V., a fellow group company. The directors have received confirmation from Teva Pharmaceuticals Europe B.V. that it has pledged its continuing support for a minimum of 12 months from the date of signing these financial statements.”
Significant events
- “During September 2024, the company completed the divestment of several intangible assets as part of a global strategic review by the Teva group to enhance its focus on core products.”
- “On 19 November 2024, the company paid a dividend of £94,000,000 to Teva Pharma Holdings Limited.”
- “The divestments made during 2023 and 2024 may lead to reduced revenues in 2025 and future years.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
2 active · 17 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| CHARLESWORTH, Stephen Michael | Director | 2020-04-29 | Feb 1967 | British |
| INNES, Kim | Director | 2016-10-01 | Aug 1968 | British |
Show 17 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| LIVINGSTONE, Andrew John Robertson | Secretary | 1998-04-01 | 2015-06-01 |
| MORE, William Jamieson | Secretary | — | 1998-03-31 |
| NELLIGAN, Tom | Secretary | 2015-06-01 | 2016-08-02 |
| PINSENT MASONS SECRETARIAL LIMITED | Corporate Secretary | 2017-03-13 | 2017-03-13 |
| BURKE, Diarmuid | Director | 1997-12-01 | 2015-03-30 |
| COOPER, Dean Michael | Director | 2018-07-12 | 2020-04-29 |
| DANIELL, Richard Gordon | Director | 2016-08-02 | 2016-10-01 |
| GOLDBERG, Anthony | Director | — | 1995-06-07 |
| HART, Richard William | Director | — | 1997-11-30 |
| JAKES, Nadine | Director | 2014-12-01 | 2016-08-02 |
| MCDONALD, Michael | Director | 2014-04-02 | 2015-03-30 |
| MORE, William Jamieson | Director | — | 1998-03-31 |
| SOLOMON, Howard | Director | — | 2014-03-31 |
| STAFFORD, Raymond Thomas | Director | — | 2014-04-02 |
| VINCENT, Sara Jayne | Director | 2014-12-01 | 2016-08-02 |
| WILLIAMS, Robert | Director | 2016-08-02 | 2018-06-27 |
| WORTH, John Christopher | Director | 1997-12-01 | 2006-06-30 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Teva Pharma Holdings Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-08-02 | Active |
Filing timeline
Last 20 of 140 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-12-17 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-10-06 | AA | accounts | Accounts with accounts type full | |
| 2024-12-16 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-10-09 | AA | accounts | Accounts with accounts type full | |
| 2023-12-21 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-08-07 | AA | accounts | Accounts with accounts type full | |
| 2023-01-03 | AA | accounts | Accounts with accounts type full | |
| 2022-12-21 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-01-07 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2021-10-03 | AA | accounts | Accounts with accounts type full | |
| 2020-12-24 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2020-11-09 | AA | accounts | Accounts with accounts type group | |
| 2020-04-29 | TM01 | officers | Termination director company with name termination date | |
| 2020-04-29 | AP01 | officers | Appoint person director company with name date | |
| 2019-12-13 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2019-10-10 | AA | accounts | Accounts with accounts type group | |
| 2019-09-30 | CH01 | officers | Change person director company with change date | |
| 2018-12-12 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2018-10-30 | AA | accounts | Accounts with accounts type group | |
| 2018-07-24 | AD01 | address | Change registered office address company with date old address new address |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 2
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
-62.5%
£23,672,000 £8,887,000
-
Cash
—
Not reported
-
Net assets
-79.7%
£67,974,000 £13,817,000
-
Employees
—
Not reported
-
Operating profit
-36.1%
£77,978,000 £49,840,000
-
Profit before tax
-35%
£83,806,000 £54,465,000
Each % is (latest − prior) ÷ |prior| for the line item as filed. Periods don't have to be exactly 12 months apart — a long or short period (typical around incorporation or year-end changes) will distort the comparison. Lines a company doesn't report are omitted. About these numbers